News

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...
Targeted Oncology2d
FDA Actions in Oncology: April 2025 Approvals and Designations
A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...
New Data At DDW 2025 Further Demonstrates The Tissuecypher® Test's Ability To Identify Patients At Increased Risk For Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled,“The ...
Le Lézard6d
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATOtm in Liver-Dominant Metastatic Breast Cancer
Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...
Morningstar6d
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of ...
Yahoo Finance2d
Castle Biosciences, Inc. (CSTL)
will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer ...
Dermatology Advisor5d
Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma
Patients receiving melphalan/hepatic delivery system had longer overall survival and disease control rates vs best alternative care.
BioSpace6d
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
About DecisionDx-UM DecisionDx-UM is Castle Biosciences’ 15-gene expression profile (15-GEP) test that uses an individual patient’s tumor biology to predict individual risk of metastasis in patients ...